[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,777,0,25,[9,47,68,91,115,134,156,181,205,234,257,284,303,329,353,372,398,423,441,458,481,502,540,560,582],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053420",false,"NCT06970275","To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","PETRiS","Inclusion Criteria :\n\nAll patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.\n\nPatients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.\n\nExclusion Criteria:\n\n* Under the age of 18 years at the time of resective surgery.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":20,"type":21},850,"ESTIMATED","OBSERVATIONAL","This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.",[25,26,27,28],"Prostate Cancers","Breast Cancer","Head and Neck Cancer","Cancer",[30,31,32,33],"PET-CT","Registry","Imaging","cancer","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2025-11-19",{"date":42,"type":21},"2031-01-15",{"name":44,"class":45},"XEOS Medical","INDUSTRY",2,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100053391","NCT05376891","Met Non Small Cell Cancer Registry (MOMENT)","Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)","Inclusion Criteria:\n\n* Participants who signed ICF\n* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)\n* Participants who are starting or are already being treated with systemic therapy\n\nExclusion Criteria:\n\n* Participants who are enrolled in a clinical trial",{"count":54,"type":21},700,"The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.\n\nThe registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.",[28],[58,59],"Disease Registry","METex14 Skipping Alterations",{"date":37,"type":38},{"date":62,"type":38},"2022-10-04",{"date":64,"type":21},"2028-04-28",{"name":66,"class":45},"EMD Serono Research & Development Institute, Inc.",66,{"id":69,"slug":4,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100053819","NCT07091968","Feasibility of a Technology-Based Intervention for Depression Referral Uptake in Cancer Survivors","Pilot Feasibility Trial to Evaluate a Technology-Enabled Approach to Enhance Depression Referral Uptake Among Cancer Survivors","Inclusion Criteria:\n\n* age \\> 18 years\n* diagnosis of cancer\n* upcoming appointment in an HCC or HCN oncology clinic within 14 days\n* English proficiency\n* ownership of a cellphone with SMS text capability.\n* elevated depressive symptoms at screening (as measured by \\> 3 on the PHQ-2)\n\nExclusion Criteria:\n\n* cognitive impairment as evaluated by attending physician\n* currently receiving counseling for depression",{"count":75,"type":21},60,"INTERVENTIONAL",[78],"NA","Depression is very common in cancer survivors but there are challenges to linking those in need of treatment efficiently to care. In this study, investigators will test the feasibility and acceptability of a new text-based approach to connect cancer survivors with depression with care.",[28,81],"Depression",{"date":37,"type":38},{"date":84,"type":38},"2026-01-16",{"date":86,"type":21},"2026-12",{"name":88,"class":89},"Medical University of South Carolina","OTHER",1,{"id":92,"slug":4,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":76,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":90},"100053947","NCT06605196","Improving Cancer Prevention and Control Through Academic-local Public Health Department Partnerships","AHD","Inclusion Criteria:\n\n* Local health department practitioners who are involved in the implementation of cancer prevention and control programs within their communities and are engaged in an academic-health department partnership.\n* Employees in academic settings currently partnering with local health departments. These partnerships could be located anywhere within the United States.\n\nExclusion Criteria:\n\n• Individuals under the age of 18 years old.",true,{"count":99,"type":21},364,[78],"The purpose of this study is to understand how to leverage structures and processes of academic health department (AHD) partnerships to facilitate implementation of cancer related evidence-based programs and policies (EBPPs).",[28],[104,105],"Improving cancer prevention and control","academic-local public health department partnerships","NOT_YET_RECRUITING","2026-07-09",{"date":37,"type":38},{"date":110,"type":21},"2026-09-30",{"date":112,"type":21},"2028-11-30",{"name":114,"class":89},"Washington University School of Medicine",{"id":116,"slug":4,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":76,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":90},"100054243","NCT07700199","AI-Driven Survivorship Care Plans (AI-SCP)","AI-SCP","Inclusion Criteria:\n\n* Adult cancer survivors\n* Age +18 years,\n* Speak and understand English\n* Affiliated with the Huntsman Cancer Institute.\n\nExclusion Criteria:\n\n* Under age 18\n* Not affiliated with Huntsman Cancer Institute\n* Unable to speak or understand English",{"count":122,"type":21},50,[78],"This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Unlike generic AI documentation tools, this system establishes benchmarks for SCP development and embeds user-centered design (UCD) directly into prompt engineering and model governance workflows.",[28],"2026-07-07",{"date":37,"type":38},{"date":129,"type":21},"2026-08-01",{"date":131,"type":21},"2027-08",{"name":133,"class":89},"University of Utah",{"id":135,"slug":4,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":76,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":90},"100053863","NCT07698314","A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer","Myo-EXERTBC","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women prescribed exercise as a SOC\n3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast\n4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n5. Women with \\> 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center\n\nExclusion Criteria:\n\n1. Any current treatment with cytotoxic chemotherapy for breast cancer\n2. Inability to safely engage in group sessions of resistance training as deemed by study PI\n3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training\n4. Pregnant women\n5. Males","FEMALE","20 Years","89 Years",{"count":145,"type":21},21,[78],"In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.",[28,26],{"date":37,"type":38},{"date":151,"type":21},"2026-06",{"date":153,"type":21},"2028-06",{"name":155,"class":89},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":157,"slug":4,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":76,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":90},"100643356","NCT07632638","Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures","Safety and Technical Evaluation of a Robotic Platform (RonovoTM) in Elective Oncological Surgery: A Prospective, Single-Arm, Multi-Specialty Registry","CONSTELAR","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Confirmed malignancy diagnosis\n3. Elective indication for robotic approach using RonovoTM\n4. Able to understand and sign informed consent\n\nExclusion Criteria:\n\n1. Formal contraindication to minimally invasive surgery\n2. Severe comorbidity prohibiting the procedure\n3. Refusal to participate or sign informed consent\n4. Emergency surgery",{"count":164,"type":21},40,[78],"CONSTELAR is a prospective, single-arm, multi-specialty registry designed to evaluate the safety and intraoperative performance of the RonovoTM robotic surgical platform in adult patients undergoing elective oncological surgery. The study enrolls patients across four surgical specialties (Digestive Surgery, Thoracic Surgery, Urology, and Gynecology) at a single academic center. Primary endpoints include 30-day and 90-day complication rates (Clavien-Dindo classification), operative times, conversion rates, estimated blood loss, and device-related technical failures. Secondary endpoints encompass length of hospital stay, Intensive Care Unit (ICU) admission, readmission\u002Freoperation rates, and oncological surgical outcomes (resection margins, lymph node harvest). The study aims to provide initial safety and feasibility data to support the regulatory pathway for the RonovoTM platform in Latin America.",[168,28],"Malignant Neoplasms",[170,171,172],"Robotic surgery","Minimally invasive surgery","Oncological surgery","2026-07-01",{"date":175,"type":38},"2026-07-02",{"date":177,"type":38},"2026-06-19",{"date":86,"type":21},{"name":180,"class":89},"Instituto do Cancer do Estado de São Paulo",{"id":182,"slug":4,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":76,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100606424","NCT07175376","Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway","Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study","Inclusion Criteria:\n\nPatients with cancer:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 65 years at the time of enrollment.\n* Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic\u002Fimmune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.\n* eFI pre-frail or frail status (available in EHR; defined as eFI \\> 0.10) within 30 days before enrollment.\n* Ability to read and understand the English language\n\nProviders:\n\n* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.\n\nExclusion Criteria:\n\nPatients:\n\n* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.\n* Chemotherapy planned at a facility outside the Atrium Health system.\n* Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).","65 Years",{"count":189,"type":21},32,[78],"The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.",[28,193,194],"Frail","Chemotherapy",[28,196,197],"Frailty Index","eFI score",{"date":175,"type":38},{"date":200,"type":38},"2026-03-16",{"date":202,"type":21},"2027-05",{"name":204,"class":89},"Wake Forest University Health Sciences",{"id":206,"slug":4,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":97,"sex":17,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":233},"100409252","NCT04609072","Connect for Cancer Prevention Study (Connect)","Connect for Cancer Prevention Study: A Prospective Cohort Study Within Integrated Healthcare Systems in the US","* INCLUSION CRITERIA:\n\nDue to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria at time of initial study invitation, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Patients or members of participating IHCS at the time of enrollment\n* Age between 30 and 70 years old at study invitation\n\nIf an individual is determined to be ineligible at the time of enrollment due to age, the individual will be allowed to re-enroll at a later time once the recruit meets the age requirement. This includes recruits that did not meet the original age requirement of 40-65 years of age but now meet the updated age range of 30-70.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria at time of initial study invitation will be excluded from participation in this study:\n\n* Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)\n* Individuals with known cognitive impairment documented in their medical record","30 Years","70 Years",{"count":214,"type":21},200000,"Background:\n\nThe National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk.\n\nObjective:\n\nTo study and better understand the causes of cancer and to find new ways to prevent it.\n\nEligibility:\n\nThe study will include 200,000 adults who get their health care from a partner health care system, are between 30 and 70 years old at enrollment, and have never had cancer. People remain eligible to join if they have or once had non-melanoma skin cancer, or a condition that may raise cancer risk (such as ductal carcinoma in situ, or DCIS).\n\nDesign:\n\nEligible recruits can sign up for Connect online by creating an account on MyConnect using their email address or phone number. After creating an account, they will complete the informed consent process. All information shared through MyConnect is secure to protect participant privacy. After joining the study, participants will be asked to answer online health surveys a few times a year, donate samples of blood, urine, and saliva every two to three years, and safely share access to their electronic health records with Connect. In the future, participants may donate unused samples that are collected at clinical visits, like tissue, stool, or blood, and may mail in samples collected at home. Participants may also share information from personal health trackers, like wearable devices or apps.\n\nThis information will help researchers study the health and behavior patterns that may affect cancer risk.\n\nIt takes time to understand the causes of cancer, so Connect will go on for many years. The longer people participate, the more researchers may learn. Participants can leave the study at any time.\n\nLearn more about Connect by visiting cancer.gov\u002Fconnectstudy....",[28,217],"General Research Use",[219,220,221,222,223,224],"Risk Factors","medical conditions","Pathology","Blood","Urine","Natural History",{"date":175,"type":38},{"date":227,"type":38},"2021-07-26",{"date":229,"type":21},"2070-12-31",{"name":231,"class":232},"National Cancer Institute (NCI)","NIH",10,{"id":235,"slug":4,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":76,"phases":242,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100354763","NCT03899155","Pan Tumor Rollover Study","Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies","Inclusion Criteria\n\n* Signed Written Informed Consent.\n* Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.\n* On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.\n* WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.\n\nExclusion Criteria\n\n* Participant is not eligible for study treatment per the Parent Study eligibility criteria.\n* Participants not receiving clinical benefit as assessed by the Investigator.\n* Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.\n* Other protocol-defined Inclusion\u002FExclusion Criteria apply",{"count":241,"type":21},1500,[243],"PHASE2","Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.",[28],[247,248],"Rollover","pan-tumor",{"date":175,"type":38},{"date":251,"type":38},"2019-08-09",{"date":253,"type":21},"2029-08-25",{"name":255,"class":45},"Bristol-Myers Squibb",399,{"id":258,"slug":4,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":76,"phases":266,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100640381","NCT07575685","Enhancing Cancer Care: RestoreMe App for Personalized Nutrition and Activity in Cancer Patients","Enhancing Cancer Care: RestoreMe Application for Personalized Nutrition and Activity in Cancer Patients","RestoreMe","Inclusion Criteria:\n\n* Age \\> 18\n* Planned to receive, or have received, cancer treatments including radiation therapy, chemotherapy, immunotherapy, or surgery\n* Must have a smartphone or other device with the ability to receive text messages, download and use mobile applications.\n* Ability to read and write English\n* Provide written informed consent to participate in the study.\n* Concurrent enrollment on other trials is permitted.\n\nExclusion Criteria:\n\n* Poorly controlled diabetes (defined as fasting glucose level \\> 200 mg\u002FdL despite attempts to improve glucose control by fasting duration and adjustment of medications).\n* Any medical condition requiring fluid restriction or nutrient restrictions.",{"count":265,"type":21},150,[78],"This is a single institution feasibility study of the updated RestoreMe app. The investigators plan to recruit 150 participants to this study with participants being recruited either prior to the initiation of their curative treatment or during and after completion of their cancer therapy. This design will allow the investigators to assess the feasibility of using the RestoreMe app in both the active treatment setting and follow up\u002Fsurvivorship setting. Information gathered from this feasibility study will inform future trial design for prospective intervention using the RestoreMe app.",[269,28,270,271],"Nutrition Aspect of Cancer","Dietary Recommendations","Mobile Applications",[273,274,275],"Patient Reported Outcomes","Biomarker","Activity","2026-06-30",{"date":175,"type":38},{"date":279,"type":21},"2026-07",{"date":281,"type":21},"2035-07",{"name":283,"class":89},"Montefiore Medical Center",{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":97,"sex":17,"minAge":289,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":76,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":90},"100630257","NCT07485322","Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center","Inclusion Criteria:\n\n* ≥ 35 years\n* Veteran of the United States Armed Forces (retired\u002Fno longer enlisted) with a prior deployment resulting in exposure (based on self-report or official records, if available) to burn pits for \\>1 week (exposure defined as on the base or close enough to the base to see the smoke from the burn pit, an area of land used for the open-air combustion of trash and other solid waste products).\n* Ability to understand and willing to sign informed consent\n* Ability to understand and willing to sign HIPAA Authorization\n\nExclusion Criteria:\n\n* No history of malignancy within the past 5 years (non-melanoma skin cancer and in situ carcinoma would still be eligible) and not currently being worked up clinically for suspicion of cancer.\n* For women of childbearing potential, not pregnant.","35 Years","85 Years",{"count":292,"type":21},100,[78],"The goal of this study is to determine the feasibility and participant satisfaction associated with a more intensive cancer screening regimen in veterans exposed to burn pits. The study results may describe the clinical and psychosocial impact such screening has on this potential population. The study hopes to share the premalignant and malignant findings identified and follow-up healthcare utilization associated with high-intensity cancer screening during the approximately 3-year study period (three annual screening assessments and an additional year of follow-up to determine participants' cancer status). The study will also explore the performance of new tools (nasal brush, multi-cancer detection blood test, and radiomic analysis) in detecting the development of cancer during the study period.",[28],{"date":175,"type":38},{"date":298,"type":38},"2026-06-17",{"date":300,"type":21},"2029-07-31",{"name":302,"class":89},"Inova Health Care Services",{"id":304,"slug":4,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":97,"sex":17,"minAge":308,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":312,"conditions":313,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":90},"100469897","NCT05398783","A Natural History Study of Metabolic Sizing in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all the following criteria for their cohort:\n\nCohort 1 - Healthy Volunteers\n\n* Male or female, aged \\>=2 years\n* In good general health as evidenced by medical history\n\nCohort 2 - Patients\n\n* Male or female, aged \\>=2 years\n* Diagnosed with diseases thought to alter metabolism or body composition (such as weight loss or gain, diabetes, renal disease, obesity, cancer, etc.) or taking medications thought to alter metabolism or body composition.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Participants over 200 kg due to the weight limit of the equipment.\n* Presence of any implanted device that would interfere with measurements.\n* Any moderate to severe limitations in mobility that would impede participation\n* Hemoglobin less than 10 g\u002FdL (in participants who would have blood drawn for research purposes).\n* Participants with dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals.\n* Participants unwilling or unable to give informed consent.\n* Participants with any other significant physical, medical, or psychiatric limitations, illness or conditions that may preclude them from completing the majority of the tests in this study per the discretion of the PI.","2 Years","99 Years",{"count":311,"type":21},2000,"Background:\n\nScientists have long used simple measures (such as height and weight) to estimate how much a person s body uses food (calories) as energy, as commonly called the metabolic rate. But metabolism varies among people with similar body sizes. Scientists now believe the old formulas for estimating metabolic rates may not work well for all people. Researchers want to find more accurate ways to measure a person s metabolism.\n\nObjective:\n\nThis natural history study will examine the relationships between metabolism, body composition, and body surface area in a wide range of people.\n\nEligibility:\n\nHealthy children and adults aged 2 years or older. Also, people aged 2 years or older with conditions that may alter metabolism. These may include diabetes, obesity, renal disease, or cancer.\n\nDesign:\n\nParticipants will spend 2 days and 1 night in the hospital. They will provide a medical history and answer questions about their activity levels, the foods they eat, and their lifestyle. They will also eat a special diet.\n\nParticipants will undergo many tests:\n\nThey will lie in a bed with a clear hood covering their head for 30 to 45 minutes to measure the gases in their breath.\n\nThey will lie on a padded table for about 15 minutes while their body is scanned.\n\nThey will stand on a platform while a 3D scanner measures their body.\n\nThey will have a test to measure how fast an electric signal moves through their body.\n\nThey will grip an instrument to measure the strength of their hands.\n\nThey will drink salty water and provide blood and urine samples.\n\nParticipants may be invited to return for these 2-day visits up to 8 times per year. Return visits must be at least 2 weeks apart.",[314,28,315,316,317],"Metabolic Disorders","Chronic Kidney Disease","Diabetes","Normal Physiology",[319,320,321,224],"Body Composition","Metabolism","Body Surface Area",{"date":173,"type":38},{"date":324,"type":38},"2022-10-25",{"date":326,"type":21},"2031-07-01",{"name":328,"class":232},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":330,"slug":4,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":76,"phases":337,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100512874","NCT05958121","IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and\u002For Refractory Solid Tumors","A Phase I\u002FII First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and\u002For Refractory Solid Tumors","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Patients must have a specific pathologically confirmed and documented advanced and\u002For metastatic solid tumor indication\n* Patients must have received or not be eligible for indicated standard-of-care treatments per cohort\n* Measurable disease according to RECIST 1.1\n* Confirmed HLA status\n* ECOG Performance Status of 0 to 1\n* Adequate baseline hematologic, hepatic and renal function, acceptable coagulation status\n\nExclusion Criteria:\n\n* Other active malignancies that require treatment or that might interfere with the trial endpoints\n* The patient is pregnant or is breastfeeding\n* History of hypersensitivity to components of IMA402 or rescue medications; hypersensitivity to or contraindication according to current SmPC for respective combination medicinal product\n* The patient has concurrent severe and\u002For uncontrolled medical disease. Any other health condition that would, in the investigator's or sponsor's judgement, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures\n* Patients with active brain metastases, history of bleeding into brain metastases, known brain metastases who are receiving therapeutic anticoagulation",{"count":336,"type":21},400,[338,243],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and\u002For refractory solid tumors.\n\nPrimary objectives:\n\n* To determine the maximum tolerated doses and\u002For recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia)\n* To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I\u002FII)\n* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)\n\nSecondary objectives:\n\n* To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I)\n* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)\n* To describe the PK of IMA402 as monotherapy and in combination (Phase I\u002FII)",[341,342,343,28],"Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","2026-06-29",{"date":173,"type":38},{"date":347,"type":38},"2023-08-09",{"date":349,"type":21},"2027-09",{"name":351,"class":45},"Immatics Biotechnologies GmbH",29,{"id":354,"slug":4,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":76,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":90},"100501166","NCT05805722","Comprehensive Tobacco Cessation for Cancer Patients and Survivors","Building a Comprehensive Tobacco Cessation Program for Cancer Patients and Survivors: \"A Breath of Fresh Air\"","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with study procedures and availability for the duration of the study\n* Have a documented history of cancer of any type, whether active or in remission\n* Identify as a current or recently-quit tobacco user\n\nExclusion Criteria:\n\n* Not a VCUHealth patient\n* Non English-speaking",{"count":360,"type":21},75,[78],"The purpose of this research study is to learn how best to incorporate tobacco cessation treatment into clinical care for cancer patients, survivors, and caregivers.",[364,28],"Tobacco Use Cessation",{"date":276,"type":38},{"date":367,"type":38},"2023-04-12",{"date":369,"type":21},"2029-09-30",{"name":371,"class":89},"Virginia Commonwealth University",{"id":373,"slug":4,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":76,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":397},"100475367","NCT05470010","Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors","The SEAMLESS Study: A Pragmatic Multi-Site Randomized Waitlist-Controlled Trial of a Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors","SEAMLESS","Inclusion Criteria:\n\n* Adult ≥ 18 years\n* Diagnosed with any type of cancer (stages I-IV)\n* Completed primary treatment (i.e. surgery, chemotherapy, radiation therapy) at least 2 weeks (14days) prior. Note: ongoing maintenance therapy, hormone-blocking therapies, intermittent bone-modifying agents, herceptin and targeted therapy with trastuzumab are not exclusionary.\n* Have access to a smartphone with data or wifi connection.\n* Willing to devote 20-30 mins of time to mindfulness practices daily during the 4-week intervention period.\n* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form (e-consent) prior to enrollment in the study to document their willingness to participate.\n* Participant is able (i.e. sufficiently fluent) and willing to complete the MBCS Journey and outcome measures in either English or French. The baseline assessment must be completed within required timelines, prior to randomization.\n* In accordance with CCTG policy, protocol intervention is intended to begin within 7 calendar days of patient randomization.\n* Participants must be willing to complete the MBCS Journey and complete the follow-up questionnaires\n\nExclusion Criteria:\n\n* Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or cognitive impairment (score of ≤ 6; as assessed by the centre CRA using the three questions from the Brief Screen for Cognitive Impairment (BSCI)) listed in the screening CRF, which could interfere with completing the intervention and\u002For the questionnaires (i.e. inability to read or write)\n* Suffering from untreated Major Depressive Disorder or other psychiatric disorders that would interfere with participation. (Note: Participants will be referred for treatment and invited to call back once in remission).\n* Previous experience practicing in-person or app-based mindfulness once a week or more within the last year.",{"count":380,"type":21},345,[78],"There is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).",[28,384],"Psychological",[386,387,388],"Cancer survivors","Smartphone app","Mindfulness",{"date":276,"type":38},{"date":391,"type":38},"2025-03-07",{"date":393,"type":21},"2026-12-31",{"name":395,"class":396},"Canadian Cancer Trials Group","NETWORK",7,{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":76,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":422},"100450216","NCT05142605","Evaluation of Grief Therapy Approaches for Bereaved Parents","Meaning-Centered Grief Therapy for Parents Bereaved by Cancer: A Multisite Randomized Controlled Trial","Parent Participant Inclusion Criteria:\n\n* A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by medical record or self-report\n* Elevated prolonged grief (PG) symptoms (PG-13-R scores of 30 or above)\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate\n\nSupport Provider Inclusion Criteria:\n\n* Must be age 18 or over as indicated by self-report\n* Has been identified by the bereaved parent participant as a support or someone important to bereaved parent\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nFamily Participant Inclusion Criteria:\n\n* A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by medical record or self-report\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nTraining Case Inclusion Criteria:\n\n* A biological, adoptive, step-parent, or legal guardian from across the United States as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child at least 6 months prior to enrollment as indicated by medical record or self-report\n* Score of 29 or below on the PG-13-R OR lost a child to a cause other than cancer OR child's additional guardian has consented as a Parent Participant and has not provided permission to share participation status OR past participants who indicate an interest in serving as a training case and, in the judgment of the Principal Investigator, would be appropriate to enroll as a training case\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  ° (Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nTraining Case Support Provider Inclusion Criteria:\n\n* Must be age 18 or over as indicated by self-report\n* Has been identified by the bereaved parent training case participant as a support or someone important to bereaved parent\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  ° (Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nParent Participant Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude completion of the assessment measures, interview or informed consent\n* Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nSupport Provider Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nFamily Participant Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nTraining Case Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude completion of the assessment measures, interview or informed consent\n* Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nTraining Case Support Provider Exclusion Criteria\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent",{"count":405,"type":21},415,[78],"The purpose of this study is to compare three types of support programs for parents who have lost a child. The study will see how these support programs affect participants' grief and depression symptoms. The three support programs are called Meaning-Centered Grief Therapy, Supportive Counseling, and Enhanced Usual Care.",[409,410,28],"Grief","Bereavement",[412,413,414],"Parental bereavement","Parents","Elevated prolonged grief symptoms",{"date":173,"type":38},{"date":417,"type":38},"2022-03-31",{"date":419,"type":21},"2027-05-31",{"name":421,"class":89},"University of Miami",5,{"id":424,"slug":4,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":90},"100421341","NCT04766515","Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms","Multicenter Observational Prospective Study of Immune Checkpoint Inhibitors in Patients With Solid Neoplasms","Inclusion Criteria:\n\n* Age at least 18 years.\n* Pathologically confirmed diagnosis of a solid tumor cancer.\n* Patients receiving treatment with immune checkpoint inhibitors.\n* Ability to understand and willingness to provide the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Patients with hematological malignancies or solid benign tumors.\n* Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.",{"count":430,"type":21},6000,"This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.",[28],"2026-06-28",{"date":276,"type":38},{"date":436,"type":38},"2020-09-01",{"date":438,"type":21},"2027-08-30",{"name":440,"class":89},"Fudan University",{"id":442,"slug":4,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":4,"leadSponsor":457,"locationsCount":90},"100060089","NCT00026650","Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy","* INCLUSION CRITERIA:\n\nROB investigator deems that it is in the best interests of the participant and the NCI\u002FROB for the participant to be seen in follow-up in the ROB clinic.\n\nParticipant is able to provide informed consent.\n\nParticipant must have a primary physician in the community to whom records and appropriate follow-up management can be given. Social services will be enlisted for any participants who lack health insurance, etc.\n\nParticipants who have received radiotherapy.\n\nAge greater than or equal to 18 years of age\n\nEXCLUSION CRITERIA:\n\nParticipants who are on an interventional research protocol at NIH at the time of enrollment.","120 Years",{"count":54,"type":21},"BACKGROUND\n\n* This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols.\n* It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, radiation modifiers,\n\nintraoperative radiotherapy, etc.\n\nOBJECTIVE\n\n-The primary objective of this protocol is to assess the late effects of treatment and the natural history of disease through collection of data from any standard procedures performed as part of follow up care on participants previously treated with radiotherapy.\n\nELIGIBILITY\n\n-Participants who received radiation therapy.\n\nDESIGN\n\n* This is a natural history protocol in which long-term follow up data will be collected from participants who received radiation therapy.\n* It will be made clear to participants in the consent form, that data collected during their follow-up may be used anonymously for publications concerning the natural history of disease processes and long-term effects of treatment.",[28],[451,452,28,224],"Late Effects","Radiation Therapy","2026-06-27",{"date":276,"type":38},{"date":456,"type":38},"2000-02-14",{"name":231,"class":232},{"id":459,"slug":4,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":90},"100644576","NCT07671846","Patient Anxiety During Magnetic Resonance Imaging","Italian Translation and Cross-cultural Validation of a Questionnaire Evaluating Patient Anxiety During Magnetic Resonance Imaging: the Magnetic Resonance Imaging-Anxiety Questionnaire (MRI-AQ)","MRI-AQ","Inclusion Criteria:\n\n* Cancer patients who will perform a WB-MRI in their clinical path\n* Age ≥ 18 years\n* Patients able to speak and read the local language(s) fluently.\n* Patients with no concomitant neurological or psychiatric disorders.\n* Acceptance and signature of informed consent\n\nExclusion Criteria:\n\n* Absolute contraindication to WB-MRI\n* Previous cancer-related medical treatments or other treatments that could have altered patients' cognition",{"count":466,"type":21},175,"This study is a cross-sectional validation project that aims to translate the MRI-Anxiety Questionnaire (MRI-AQ) into Italian and adapt it culturally for cancer patients undergoing whole-body MRI. The protocol will recruit 175 adult patients at the European Institute of Oncology, use a forward-backward translation process, and evaluate the Italian version with the MRI-AQ itself plus the MRI Fear Survey Schedule (MRI-FSS). The main statistical goal is to show that the Italian version is not inferior to the original in terms of internal consistency. The ultimate purpose is to provide a specific, validated tool for measuring MRI-related anxiety in Italian oncology patients.",[28],[470,471],"Magnetic Resonance Imaging","Patient anxiety","2026-06-25",{"date":474,"type":38},"2026-06-26",{"date":476,"type":38},"2026-05-06",{"date":478,"type":21},"2027-02-28",{"name":480,"class":89},"European Institute of Oncology",{"id":482,"slug":4,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":76,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":90},"100633248","NCT07524218","Effect of Meal Timing During Adjuvant Treatment for Cancer","Effect of Meal Timing During Adjuvant Treatment for Cancer: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years (no upper age limit)\n* Any sex or gender\n* Histologically or cytologically confirmed solid tumor treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and\u002For radiation per standard of care)\n* BMI ≥18.5 kg\u002Fm2\n* Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions\n\nExclusion Criteria:\n\n* No plan for systemic adjuvant therapy after surgery\n* Strictly adhering to a \\\u003C10-hour eating window on most days\n* Regular overnight shift work (≥1 night shift per week)\n* Dependent on parenteral or enteral nutrition\n* Pregnant or breastfeeding\n* Active second malignancy requiring systemic therapy (exceptions: non-melanoma skin cancers or in situ cervical cancers adequately treated)\n* Severe psychiatric, cognitive, or social conditions that would interfere with adherence to study procedures",{"count":122,"type":21},[78],"The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response, patient well-being and long-term metabolic health. In alignment with these priorities, we propose to focus on patients with histologically or cytologically confirmed solid tumors treated with curative-intent surgical resection and planned initiation of systemic adjuvant therapy (chemotherapy, targeted therapy, immunotherapy, and\u002For radiation per standard of care).\n\nA promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.",[28],[492,493,494],"Time-restricted eating","Time restricted eating","Meal timing",{"date":344,"type":38},{"date":497,"type":21},"2026-07-06",{"date":499,"type":21},"2029-08-31",{"name":501,"class":89},"Fred Hutchinson Cancer Center",{"id":503,"slug":4,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":510,"conditions":511,"keywords":525,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":539},"100618120","NCT07327489","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies","ELEPHAS-05","Inclusion Criteria:\n\n1. Able and willing to provide informed consent for participation\n2. Age ≥18 years at time of consent.\n3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.\n4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n\nExclusion Criteria:\n\n1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.\n2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.\n3. Pregnant person(s).",{"count":311,"type":21},"This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.",[28,512,513,514,515,516,517,518,519,27,520,521,522,523,524],"Immunotherapy","Advanced Solid Tumors Cancer","Bladder Cancer","TNBC, Triple Negative Breast Cancer","Colorectal Cancer","DMMR Colorectal Cancer","MSI-H Colorectal Cancer","Endometrial Cancer","Kidney Cancer","Liver Cancer","NSCLC (Non-small-cell Lung Cancer)","Skin Cancer","Melanoma (Skin Cancer)",[512,526,527,28,32,528,529,530,531,532],"Live Tumor Biopsy","Elephas","Tumor Cutting","Treatment Response","Core Needle Biopsy","Forceps Biopsy","Punch Biopsy",{"date":344,"type":38},{"date":535,"type":38},"2025-04-14",{"date":537,"type":21},"2038-04",{"name":527,"class":45},8,{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":76,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":46},"100585641","NCT06905002","Enhancing the Patient Journey to Clinical Trial Enrolment With Navigation to Optimize Accrual","Enhancing the Patient Journey to Clinical Trial Enrolment With Navigation to Optimize Accrual: A Pilot Study for a Prospective, Pragmatic Multi-centre, Stepped Wedge, Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Limited to Thunder Bay and Winnipeg health care professionals and patients;\n\nExclusion Criteria:\n\n* People outside of these two expansion sites",{"count":547,"type":21},300,[78],"Less than 5% of patient enter clinical trials, despite the fact that many patients facing cancer are recommended to seek out clinical trials. One challenge of finding a clinical trial, is the lack of clinical trials at the patient's home cancer centre. The Clinical Trials Navigator (CTN) program was established to help patients, their families and heath care providers navigate the clinical trials systems across Canada in order to identify meaningful clinical trials for patients and help them enter those trials.\n\nThe CTN program was piloted in Windsor, Ontario and increased clinical trials accrual for this population by 8%. This study plans to roll out to twenty centres across Canada, mimicing the process. This implementation of the CTN program will be tested by adding centres in a sequential fashion until all centres are added over the 12 month period.\n\nThe objectives are improved patient enrollment which will be measured by embedded CTNs in each cancer centre, and reporting to the central site.\n\nPre- and post-implementation structured interviews with administrators, physicians, patients and allied health care professionals will be used to assess uptake of the CTN program in each centre and reveal potential barriers to successful implementation of a nation-wide CTN program.\n\nThe ability of the current CTN program to upscale to twenty centres will be measured by turn-around times of patient reports and through the structured interviews.",[28],[552],"Clinical trials navigator",{"date":276,"type":38},{"date":555,"type":38},"2025-04-01",{"date":557,"type":21},"2028-07",{"name":559,"class":89},"Windsor Regional Hospital",{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":17,"minAge":565,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":76,"phases":568,"briefSummary":569,"conditions":570,"keywords":572,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":90},"100484445","NCT05588141","A Phase I\u002FII Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","* INCLUSION CRITERIA:\n* Participants must have diffuse glioma, WHO grades 2-4, histologically confirmed by Laboratory of Pathology, NCI.\n* IDH1 or IDH2 mutation status confirmed by TruSight(TM) Oncology 500 performed in LP, NCI or prior documentation of IDH1 or IDH2 mutation status\n* Participants must have received prior treatment (e.g., radiation, conventional chemotherapy, or vorasidenib) prior to disease progression.\n* Participants must have recurrent disease, proven histologically or by imaging studies\n* Participants who have undergone prior surgical resection are eligible for enrollment to cohorts 1-4.\n* Age \\>15 years\n* Karnofsky \\>70%\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes \\>=3,000\u002Fmicroliter\n  * absolute neutrophil count (ANC) \\>=1,500\u002Fmicroliter\n  * platelets \\>100,000\u002Fmicroliter\n  * total bilirubin \\\u003C=2x ULN (ULN 1.3 mg\u002Fdl) except for participants with Gilbert Syndrome\n  * AST \\\u003C 3x ULN (ULN 34U\u002FL)\n  * ALT \\\u003C 3x ULN (ULN 55U\u002FL)\n  * serum creatinine \\\u003C 1.5 mg\u002FdL\n  * calculated creatinine clearance by CKD-EPI equation \\> 60 cc\u002Fmin\n* Participants must have recovered from the adverse effects of prior therapy to grade 2 or less (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0)\n* Individuals of child-bearing potential (IOCBP) and men must agree to use highly effective contraception (hormonal, intrauterine device (IUD), abstinence, tube ligation, partner has had a previous vasectomy) at the study entry, for the duration of study treatment, and up to 3 months after the last dose of zotiraciclib\n* Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 3 months after study treatment discontinuation\n* Participants must be scheduled for brain tumor biopsy or surgical resection at NIH (Cohort 5 only)\n* The ability of a participant, parent or legal guardian of minor participant to understand and the willingness to sign a written informed consent document. No Legally Authorized Representative can provide initial consent.\n\nEXCLUSION CRITERIA:\n\n* More than one disease relapse in those with initial diagnosis of WHO grade 3-4, or more than two disease relapses in those with initial diagnosis of WHO grade 2 for Phase II. For Phase I enrollment, there are no limits on the number of prior recurrences.\n* Prior therapy with:\n\n  * any investigational agent (including IDH mutant inhibitor) and\u002For standard of care cytotoxic therapy within 28 days prior to treatment initiation\n  * vincristine within 14 days prior to treatment initiation\n  * nitrosoureas within 42 days prior to treatment initiation\n  * procarbazine within 21 days prior to treatment initiation\n  * non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, within 7 days prior to treatment initiation\n  * surgery within 14 days prior to treatment initiation\n  * radiation therapy within 30 days prior to treatment initiation\n  * bevacizumab for tumor treatment. Note: participants who received bevacizumab for symptom management, including but not limited to cerebral edema, or pseudo progression can be enrolled\n* Prolonged QTc \\>470ms as calculated by correction formula on screening electrocardiogram (ECG) (QTCf can be used; QTCb can be used for participants with sinus bradycardia)\n* Prior invasive malignancies within the past 3 years prior to study treatment initiation (with the exception of non-melanoma skin cancers, carcinoma in situ of the cervix, melanoma in situ, or any localized cancer for whom the systemic standard of care therapy is not required)\n* History of allergic reactions attributed to compounds of similar chemical composition to zotiraciclib, such as flavopiridol\n* Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed at screening)\n* Uncontrolled intercurrent illness or social situations that would limit compliance with study requirements\n* Uncontrolled primary diabetes mellitus","15 Years",{"count":567,"type":21},96,[338,243],"Background:\n\nDiffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.\n\nObjective:\n\nTo see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.\n\nEligibility:\n\nPeople aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 genes.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have an MRI of their brain. A new biopsy may be needed if previous results are not available.\n\nZotiraciclib is a capsule taken by mouth with a glass of water. Participants will take the drug at home on days 1, 4, 8, 11, 15, and 18 of a 28-day cycle. They may also be given medications to prevent side effects of the study drug. The schedule for taking the study drug may vary for participants who will undergo surgery.\n\nParticipants will be given a medication diary for each cycle. They will write down the date and time of each dose of the study drug.\n\nParticipants will visit the clinic about once a month. They will have a physical exam, blood tests, and tests to evaluate their heart function. An MRI of the brain will be repeated every 8 weeks.\n\nParticipants may remain in the study for up to 18 cycles (1.5 years).",[571,28],"Brain Tumor",[571,573,574,575],"Glioma","Idh Mutation","Recurrent Disease",{"date":474,"type":38},{"date":578,"type":38},"2023-05-16",{"date":580,"type":21},"2032-08-02",{"name":231,"class":232},{"id":583,"slug":4,"hasResults":11,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":90},"100514043","NCT05973344","Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients","TADIG-P","* Age ≥ 18 years old\n* ECOG performance status ≤ 1\n* Must have histologically or cytologically confirmed tumour, eligible for treatment with ICI as standard-of-care alone or in combination with another ICI, ICI with chemotherapy, ICI with radiotherapy, or ICI with targeted therapy with no restrictions on number of prior systemic therapies\n* Adequate bone marrow function as defined below\n\n  * Absolute neutrophil count ≥ 1500\u002FµL or 1.5x109\u002FL\n  * Hemoglobin ≥ 9 g\u002FdL\n  * Platelets ≥ 100000\u002FµL or 100x109\u002FL\n* Adequate liver function as defined below\n\n  * Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome \\\u003C 3xUNL is allowed\n  * AST (SGOT)\u002FALT (SGPT) ≤ 3.0 x ULN\n  * Alkaline phosphatase ≤ 3.3 x ULN\n* Adequate renal function as defined below\n\n  \\_- Creatinine ≤ 1.5 x UNL or creatinine clearance \\> 60 mL\u002Fmin\n* Patient monitored for their cancer at CHU of Brest\n* Did not oppose for their samples and clinical data to be used for translational research\n* Non-opposition form obtained prior to any study related procedure\n\nExclusion Criteria:\n\n* Patient with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study\n* Patient already receiving ICI\n* Primary immunodeficiency and\u002For history of allogenic transplantation\n* Current active infection\n* Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection)\n* Subject of guardianship (tutorship, curatorship)\n* Active pregnancy",{"count":589,"type":21},200,"The goal of this observational study is to explore the value of blood biomarkers for the purpose of predicting irAE development in cancer patients treated with immune checkpoint inihibitors (ICI) alone or in combination with other treatments (chemotherapy, radiotherapy and targeted therapy).\n\nData and blood samples will be collected from participants at different time points as part of routine follow-up visits. Data and blood samples will be analysed. Analysis will include the characterization of immune cells by mass and flow cytometry.",[28],[593],"immunotherapy","2026-06-24",{"date":474,"type":38},{"date":597,"type":38},"2024-02-09",{"date":599,"type":21},"2030-02-09",{"name":601,"class":89},"University Hospital, Brest",""]